Trump's trade deals with the EU and Japan pave the way for the stock market to end with it's third straight annual gain of ...

Sarepta Therapeutics ( NASDAQ: SRPT) was upgraded to Neutral from Underweight at J.P. Morgan as it sees FDA's Elevidys hold removal recommendation in ambulatory patients as a clear win.

Carvana Co. (NYSE:CVNA) is one of the best multibagger stocks according to hedge funds. On July 25, 2025, Oppenheimer analyst ...

The strategist — an industry veteran of 40 years who joined Goldman Sachs in 2002 — spoke to Bloomberg News about the outlook ...

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.

Visa and Mastercard are expected to report higher quarterly profits this week on steady consumer spending, and analysts will ...

This isn’t a generic re-run. These screenings are a testament to Nolan’s continued support for the IMAX format and enable ...

Emminent filmmaker Christopher Nolan has come under fire for shooting a few portions of his upcoming much-anticipated film The Odyssey in Dakhla, a city in Morocco-occupied Western Sahara which has ...

Jensen Huang believes questions of whether artificial intelligence (AI) could destroy humanity are fear-mongering — and get in the way of progress. The founder of Nvidia, which makes the computer ...

The S&P 500 could match its best set of annual gains in three decades this year, analysts at Oppenheimer Asset Management say, as the tailwind from trade deals and improved corporate earnings carries ...